GI Dynamics Inc  

(Public, ASX:GID)   Watch this stock  
Find more results for Timothy Switzer�
0.250
0.000 (0.00%)
Dec 19 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.25 - 0.25
52 week 0.23 - 0.91
Open 0.25
Vol / Avg. 137,000.00/280,104.00
Mkt cap 130.66M
P/E     -
Div/yield     -
EPS -0.12
Shares 94.80M
Beta     -
Inst. own     -
Jan 12, 2015
GI Dynamics, Inc at JPMorgan Healthcare Conference Add to calendar
Dec 4, 2014
GI Dynamics, Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 11, 2014
GI Dynamics Inc Extraordinary Shareholders Meeting - Webcast
Nov 5, 2014
Q3 2014 GI Dynamics Inc Earnings Call - Webcast
Oct 31, 2014
Q3 2014 GI Dynamics Inc Earnings Release
Oct 7, 2014
GI Dynamics Investor Call - Webcast
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1991.79% -1577.74%
Operating margin -1921.02% -1545.72%
EBITD margin - -1526.16%
Return on average assets -62.79% -60.19%
Return on average equity -71.10% -68.36%
Employees 38 -
CDP Score - -

Address

ONE MAGUIRE ROAD
LEXINGTON, MA 02421
United States - Map
+1-781-3573310 (Phone)
+1-781-3573301 (Fax)

Website links

Description

GI Dynamics, Inc. is the developer and marketer of EndoBarrier, a device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is approved and commercially available in multiple countries outside the United States. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. The Company has developed, and continues to develop, technologies to deliver, implant and remove devices in the gastrointestinal (GI), tract. The primary purpose of these devices is to alter the GI function such that improvements in glucose control and weight loss occur. The primary product it has developed is the EndoBarrier Gastrointestinal Liner, or implant. The implant contains an anchor and a 60 centimeters impermeable sleeve that lines the duodenum and jejunum.

Officers and directors

Andy Levine Chief Technology Officer
Age: 54
Karl-Heinz Blohm Ph.D. Vice President - International Sales
Sherrie Coval-Goldsmith Vice President - Clinical and Regulatory Affairs
Anthony Tremaglio Senior Director of Marketing
Gerd Gottschalk Reimbursement Director
David Maggs M.D. Chief Medical Officer
Age: 47
Anthony Switzer Commercial Development - Australia
Michael Donald Dale President, Chief Executive Officer, Director
Age: 53
Jack Edward Meyer Independent Non-Executive Chairman of the Board
Age: 63
Michael A. Carusi Non-Independent Non-Executive Director